so some consider that the pattern of atrophy localizes particular cognitive functions. in semD, in particular, the neuro psychological characteristics of the syndrome and the prominent anterior temporal lobe atrophy are posited to identify the site of an amodal semantic 'hub' (Figure 1 ) 5 , the function of which is to allow context-dependent access to widely distributed neural representations of components of semantic (conceptual) knowledge. Certain concerns arise, however, when efforts to localize semantic processes to discrete cortical areas are derived from studies on patients with semD. in particular, the results seem to conflict with prior evidence in the literature. evidence from the aphasic stroke literature and from the behavioral consequences of anterior temporal lobe resection to treat temporal lobe epilepsy suggest that semantic knowledge resides in more-posterior regions of temporal and inferior parietal cortex. the debate regarding localization of semantic knowledge has also been fueled by conflicting results from various functional imaging studies on normal individuals. 6, 7 By contrast, the location of maximal atrophy in PnFa and lPa and the site of acute stroke resulting in Broca and conduction aphasia, respectively, correspond reasonably well.
Despite generating considerable interest from a research perspective, the anatomy of cognition is of relatively minor clinical importance. the two articles published in Neurology ask the question that will interest patients and their clinicians most; namely, in the absence of specific diagnostic tests, can an experienced clinician infer pathology after a clinical consultation and/or inspection of an mri scan? the effective application of future disease-modifying agents will depend on the ability of clinicians to identify suitable candidates to receive these treatments. interpretation of the findings from both articles, and particu larly the Pereira et al. study, suggests that much larger series are required before the pathological spe cificity of clinical and imaging data is established. the authors of the articles acknowledge that additional pathological subgrouping based on factors, such as the presence or absence of a progranulin mutation, or other genetic data will be necessary. the discovery of specific blood or cerebrospinal fluid markers or, failing that, Pet radioligands 8 that are specific for tau-positive or ubiquitin-positive occlusions would also assist the realization of this goal. administration of rtPa was at the discretion of the local provider rather than part of a protocol. in some cases, thrombolytic therapy was administered at a communitybased medical center before referral to an iPss-affiliated center. 15 children received rtPa, representing 2% of children in the regis try and 3% of children enrolled from us and Canadian centers. interestingly, the children who received rtPa were all from the us (n = 13) or Canada (n = 2). nine children received int ravenous t hrombolysis and six children underwent intra-arterial thrombo lysis. seven of the 15 children (47%) were treated outside the suggested time windows for t hromb o lysis in adults (3 h for intravenous rtPa and 6 h for intra-arterial rtPa at the time of enrollment in the study). median times to treatment were 3.3 h (range 2-52 h) for intravenous rtPa and 4.5 h (range 3.8-24 h) for intra-arterial rtPa. two deaths occurred, both of which were unrelated to thrombolysis. Four asymptomatic and no symptomatic intra cranial hemorrhages were recorded. the children enrolled in the iPss and receiving rtPa were younger on average, were more likely to receive rtPa outside the established adult time frame, and tended to show poorer neurological outcomes than children in previously published case reports, although the absolute numbers were small and none reached statistical signifi cance. the authors acknowledge that a publication bias exists, with the individual case studies tending to report short treatment intervals and positive outcomes. their findings also emphasize the need for a safety and dose-finding study in children.
the amlie-leFond et al. 3 and Janjua et al. 2 studies show that 1-3% of children with ischemic stroke are currently receiving thrombolytic therapy. For comparison, at many centers 5-10% of adult patients with stroke receive intravenous rtPa. several issues limit the number of children who will be suitable candidates for thrombolysis. Children with stroke often present for medical care in a delayed fashion, owing to a lack of awareness of childhood stroke among parents and physicians. 4 the incidence of ischemic stroke in children is much lower than in adults (~2 per 100,000 person-years in children 5 versus 158 per 100,000 person-years in adults). 6 stroke mimics, such as postictal paralysis after a seizure or complicated migraine, are also more common in children than in adults, with these conditions accounting for 21% of cases seen by a pediatric brain-attack team. 7 mri confirmation of cerebral ische mia is important in children before thrombo lysis is administered, and this can further delay the 'door-to-needle' time for this treatment. Certain stroke subtypes in children, such as cerebral arteriopathies, might be less responsive to rtPa than others. these factors all reduce the size of the pool of children who could be eligible for thrombo lysis. more frustrating, however, is the fact that even when a child who seems to be a good candidate for thrombo lytic therapy pre sents to a physician, no data are available on dosing, safety and efficacy. whether the adult dose of 0.9 mg/kg body weight is a safe and effective dose in children is unclear. of particular relevance in this context are reports of developmental variations in the coagulation and fibrino lytic systems, which might affect rtPa dosing. 8 what recommendations can be made on the basis of the available data? when a clinician is faced with a child with possible acute arterial ischemic stroke, urgent consultation with and transfer to a center with pediatric stroke expertise should be strongly considered. the clinician should be aware that stroke mimics exist and that imaging confirmation of ischemic stroke is required in children (rather than simply a head Ct scan to confirm the absence of hemorrhage, as is performed in adults before rtPa treatment). if thrombolytic therapy is con sidered, physicians should recog nize that the outcome could be inferior to that seen in case reports. Physicians caring for children are accustomed to prescribing medications that have been insufficiently studied in this age group and are, therefore, being given off label. Considerable care should be taken, however, when adopting this approach for thrombolytic therapy. encouragingly, the niH stroke Progress review Group in 2006 identified clinical trials in pediatric stroke as a top priority, and specifically mentioned the need for safety data on rtPa use in children. 9 many challenges lie ahead but, hopefully, a dosefinding study for thrombolysis in pediatric stroke is on the horizon.
